Class II · Moderate risk
DISCOUNT drug mart
Presence of foreign substance: small metallic particles in chewable tablets.
FDA drug recalls in 2026
Every FDA drug recall initiated in 2026, newest first, with its risk class, status and the reason the FDA recorded. Use the cause and risk filters to narrow the year down.
563 recalls, newest first.
Class II · Moderate risk
CAREone
Presence of foreign substance: small metallic particles in chewable tablets.
Class II · Moderate risk
CAREone
Presence of foreign substance: small metallic particles in chewable tablets.
Class II · Moderate risk
MARKET BASKET ANTACID Calcium Carbonate 1000 mg
Presence of foreign substance: small metallic particles in chewable tablets.
Class II · Moderate risk
24/7 life BY 7-ELEVEN
Presence of foreign substance: small metallic particles in chewable tablets.
Class II · Moderate risk
Extra strength Antacid Calcium Carbonate 750 mg
Presence of foreign substance: small metallic particles in chewable tablets.
Class II · Moderate risk
Good Neighbor Pharmacy
Presence of foreign substance: small metallic particles in chewable tablets.
Class II · Moderate risk
Good Neighbor Pharmacy
Presence of foreign substance: small metallic particles in chewable tablets.
Class II · Moderate risk
Haleon Calcium Carbonate Tums Antacid
Presence of foreign substance: small metallic particles in chewable tablets.
Class II · Moderate risk
Haleon Calcium Carbonate Tums Antacid
Presence of foreign substance: small metallic particles in chewable tablets.
Class II · Moderate risk
KIRKLAND Signature
Presence of foreign substance: small metallic particles in chewable tablets.
Class II · Moderate risk
Aripiprazole Tablets USP
Product Mix-Up: A bottle containing Voriconazole Tablets 50 mg was labelled and distributed as Aripiprazole Tablets USP 30 mg.
Class II · Moderate risk
Alyacen 7/7/7
Failed Impurities/Degradation Specifications: This recall is being initiated due to out-of-specification results total impurities.
Class II · Moderate risk
Niacin Extended-release Tablets
Failed Dissolution Specifications: during 12M LT stability testing OOS low for Stage 3 dissolution at the 24-hour timepoint.
Class II · Moderate risk
Xyvona (levorphanol tartrate tablets)
Labeling: Not Elsewhere Classified. This recall has been initiated in response to the denial by FDA of marketing the product under the proprietary name Xyvona
Class II · Moderate risk
Xyvona (levorphanol tartrate tablets)
Labeling: Not Elsewhere Classified. This recall has been initiated in response to the denial by FDA of marketing the product under the proprietary name Xyvona
Class II · Moderate risk
Zep, Alcohol Sanitizer Spray
Microbial contamination of sterile products
Class II · Moderate risk
safco SensiCaine-Ultra
Defective container:may contain bottles with incomplete seals
Class II · Moderate risk
PureLife
Defective container:may contain bottles with incomplete seals
Class II · Moderate risk
Dental City TOPICAL ANESTHETIC GEL
Defective container:may contain bottles with incomplete seals
Class II · Moderate risk
Burkhart topical anesthetic gel
Defective container:may contain bottles with incomplete seals
Class II · Moderate risk
DHP Topical Anesthetic Gel
Defective container:may contain bottles with incomplete seals
Class II · Moderate risk
Quala Dental Products
Defective container:may contain bottles with incomplete seals
Class II · Moderate risk
Pearson Quality Topical Anesthetic Gel
Defective container:may contain bottles with incomplete seals
Class II · Moderate risk
Clomiphene Citrate USP Active Pharmaceutical Ingredient
cGMP deviations